CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

22-052

APPROVAL LETTER

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 22-052

Critical Therapeutics, Inc.
60 Westview Street
Lexington, MA 02421
Attention: Roberta Tucker, R.Ph.

Dear Ms. Tucker:

Please refer to your new drug application (NDA) dated July 30, 2006, received July 31, 2006, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Zyflo CR (zileuton) extended release tablets.

We acknowledge receipt of your submissions dated September 5, 8, and 18, and November 1 and 16, 2006, and February 8, 23 and 26, April 12, 2007, and May 29 and 30, 2007.
This new drug application provides for the use of Zyflo CR (zileuton) extended release tablets for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text (copy enclosed) and with the minor editorial revisions to the carton and container labels listed below.

1. Change the product name on the carton and container labels to Zyflo CR (zileuton) extended-release tablets.
2. Add the statement, "2 Tablets BID" near the bottom of the principle display panel of the carton and container labels.

Within 21 days of the date of this letter, submit content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at http://www.fda.gov/oc/datacouncil/spl.html, that is identical in content, to the submitted labeling dated May 30, 2007. Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission **"SPL for approved NDA 22-052."**

Please submit the final printed carton and container labels electronically that are identical to the carton and immediate container labels submitted on February 8, 2007, incorporating the minor editorial revisions described above.Alternatively, you may submit 12 paper copies of the final printed carton and container labels as soon as they are available but no more than 30 days after they are printed. Individually mount 6 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission **"Final Printed Carton and Container Labels for approved NDA 22-052."** Approval of this submission by FDA is not required before the labeling is used. Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are waiving the pediatric study requirement for ages 0 to 4 years and deferring pediatric studies for ages 5 to 11 years for this application.

Your deferred pediatric studies required under section 2 of the Pediatric Research Equity Act (PREA) are considered required postmarketing study commitments. The status of these postmarketing studies shall be reported annually according to 21 CFR 314.81. These commitments are listed below.

Deferred pediatric study under PREA for the prophylaxis and chronic treatment of asthma in pediatric patients - 4 to 11 years of age.

Final Report Submission: June 1, 2010

Submit final study reports to this NDA. For administrative purposes, all submissions related to this/these pediatric postmarketing study commitment(s) must be clearly designated **"Required Pediatric Study Commitments"**.

We remind you of the agreements made in your submission dated April 12, 2007, to submit the following information to the approved NDA via supplements as described below.

1. Additional information to support the methods validation (CBE-0).
2. Data from [redacted] consecutive batches to support discontinuation of [redacted] testing (Prior Approval)
3. Stability data for the first [redacted] months of stability data on three commercial scale validation batches. (CBE-0).

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to the Division of Pulmonary and Allergy Products and two copies of both the promotional materials and the package insert directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

Please submit one market package of the drug product when it is available.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Anthony M. Zeccola, Senior Regulatory Management Officer, at (301) 796-1318.

Sincerely,

{See appended electronic signature page}

Badrul A. Chowdhury, M.D., Ph.D.
Director
Division of Pulmonary and Allergy Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Badrul Chowdhury
5/30/2007 04:37:49 PM